Indivior PLC (NASDAQ:INDV – Get Free Report) was the target of a large increase in short interest in July. As of July 15th, there was short interest totalling 601,700 shares, an increase of 532.0% from the June 30th total of 95,200 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 320,700 shares, the days-to-cover ratio is currently 1.9 days.
Wall Street Analyst Weigh In
INDV has been the subject of a number of research analyst reports. Piper Sandler initiated coverage on shares of Indivior in a report on Tuesday. They set an “overweight” rating and a $22.00 price objective for the company. Craig Hallum cut their target price on shares of Indivior from $37.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, July 10th.
Institutional Trading of Indivior
Indivior Price Performance
Shares of INDV stock traded down $0.30 on Friday, reaching $12.79. The company’s stock had a trading volume of 1,487,673 shares, compared to its average volume of 920,827. The stock’s fifty day simple moving average is $15.09 and its 200-day simple moving average is $17.64. Indivior has a 1 year low of $9.14 and a 1 year high of $24.11. The company has a current ratio of 0.92, a quick ratio of 0.74 and a debt-to-equity ratio of 23.50. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 1,279.00 and a beta of 0.69.
Indivior (NASDAQ:INDV – Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.01). The company had revenue of $284.00 million during the quarter, compared to the consensus estimate of $300.00 million. Indivior had a negative return on equity of 4,735.71% and a negative net margin of 12.29%. Analysts forecast that Indivior will post 1.76 earnings per share for the current fiscal year.
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Why Call Options Volume for These 2 Stocks Spiked Together
- What Are Dividends? Buy the Best Dividend Stocks
- MarketBeat Week in Review – 7/22 – 7/26
- 5 Top Rated Dividend Stocks to Consider
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.